Study to Assess the Safety, Tolerability, PK and PD Response of PE0139 Injection in Adult Subjects With T2DM

NCT02581657 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: PE0139 Injection
DRUG: Placebo Injection

Sponsor

PhaseBio Pharmaceuticals Inc.